Common immunosuppressant found not useful in COVID-19

9 August 2022

A trial testing the use of cyclosporine in the treatment of COVID-19 has been stopped after independent data monitors decided it would likely fail.

The trial is being run by Quantum Leap Healthcare Collaborative (QLHC), a charity founded in 2005 as a collaboration between medical researchers at University of California, San Francisco and Silicon Valley entrepreneurs.

The company had hoped that cyclosporine, a calcineurin inhibitor and a well-known immunosuppressant, would be able to offer beneficial anti-inflammatory effects.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK